Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported positive Phase 1 results for SPY003, its Anti-IL-23 antibody for inflammatory bowel disease. The treatment has a half-life of 85 days, allowing for less frequent dosing. Analyst Julian Harrison maintains a Buy rating with a $70 price target, praising the extended half-life and financial stability.

Harrison also highlights Spyre’s capability to combine multiple monoclonal antibodies into a single treatment. The company is well-funded until the second half of 2028. Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a biotech firm focusing on antibody-based therapies for immune-related conditions like inflammatory bowel disease.

While SYRE shows promise, other AI stocks may offer greater upside potential with less risk. For insight on undervalued AI stocks and trends, explore the free report on the best short-term AI stock. Follow up on potential investment opportunities with stocks expected to double in 3 years and hidden AI stocks to consider.

Read more at Yahoo Finance: Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003